Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around the globe. In response, here are two related resources: First, WHO and the Global AMR R&D Hub jointly author an update on the state of incentives for R&D. Their most current report is dated 14 Oct
Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We start the new year with good news from Rome! On Saturday 28 December 2024, the Italian Senate passed the government’s 2025 budget, giving parliament’s final approval to a financial package which includes a pull incentive for innovative antibiotics. As promised by Minister
Dear All (with thanks to Louise for co-authoring and with a wonkish alert … settle in for the ride!), Today’s newsletter discusses the intersection of three themes around antibiotic access. Recall first how the paper by Baraldi et al. (1 Dec 2024 newsletter) taught us that there are at least six variations to the idea
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Aside: Please refer to our UNGA 2024 webpage for additional post-HLM notes and updates. 28 Oct 2024 addendum and another way to get a view of the day: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. Dear All (and with thanks to Damiano
Dear All, As we’ve discussed previously (1 Oct 2024 newsletter), the HLM on AMR at UNGA 2024 is but one stop along the road to global action on AMR (acronymics: HLM on AMR at UNGA 2024 = High-Level Meeting on AMR at the 2024 UN General Assembly). In follow-up, we now have two AMR-related declarations from